{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:18:25Z","timestamp":1775056705089,"version":"3.50.1"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Limited prospective data exist on the role of adding taxane to standard chemotherapy in the first-line treatment of advanced biliary tract cancers, especially in the Asian population, where biliary tract cancers are most prevalent.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the efficacy and safety of polyethoxylated castor oil\u2013free polymeric micelle formulation of paclitaxel (hereafter, polymeric micellar paclitaxel), in combination with gemcitabine and cisplatin in patients with untreated advanced biliary tract cancers.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This open-label, phase 3 randomized clinical trial was conducted across 7 centers in South Korea from September 1, 2019, to October 31, 2022. Patients were eligible if they had previously untreated, locally advanced unresectable, recurrent, or metastatic adenocarcinoma of the bile duct, were aged 19 to 79 years, had an Eastern Cooperative Oncology Group Performance Status of 0 to 2, and had measurable or evaluable lesions according to Response Evaluation Criteria in Solid Tumorsversion 1.1.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n \n Patients were randomized to receive either polymeric micellar paclitaxel, 100 mg\/m\n 2<\/jats:sup>\n ; gemcitabine, 800 mg\/m\n 2<\/jats:sup>\n ; and cisplatin, 25 mg\/m\n 2<\/jats:sup>\n ; on days 1 and 8 or gemcitabine, 1000 mg\/m\n 2<\/jats:sup>\n , and cisplatin, 25 mg\/m\n 2<\/jats:sup>\n , on days 1 and 8 every 21 days. A total of 9 cycles were planned for both groups.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was overall survival. Secondary end points included investigator-assessed and blinded independent central review\u2013assessed progression-free survival, objective response rate, and safety.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 150 patients (median [range] age, 65 [41-79] years; 87 [58%] male) were randomly assigned to the study (74 in the gemcitabine and cisplatin combined with polymeric micellar paclitaxel group and 76 in the gemcitabine and cisplatin group). The study was prematurely terminated due to slow patient accrual. The median (IQR) follow-up duration was 10.4 (6.5-16.7) months. The median overall survival was 12.0 (95% CI, 9.9-15.8) months in the gemcitabine and cisplatin combined with polymeric micellar paclitaxel group and 11.1 (95% CI, 9.7-13.5) months in the gemcitabine and cisplatin group (hazard ratio, 0.94; 95% CI, 0.63-1.41;\n P<\/jats:italic>\n \u2009=\u2009.76). Both blinded independent central review\u2013assessed and investigator-assessed progression-free survival as well as the objective response rates did not differ significantly between the 2 groups. No unanticipated safety signals were observed.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial, gemcitabine and cisplatin combined with polymeric micellar paclitaxel did not improve survival compared with gemcitabine and cisplatin combined in patients with previously untreated advanced biliary tract cancer. This study provides further evidence regarding the limitations of intensified chemotherapy with the addition of taxanes in advanced biliary tract cancer.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n cris.nih.go.kr identifier:\n KCT0003726<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.34560","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:00:47Z","timestamp":1759330847000},"page":"e2534560","source":"Crossref","is-referenced-by-count":2,"title":["Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Hyehyun","family":"Jeong","sequence":"first","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changhoon","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilhwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hun","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Ho","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwonoh","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medical Oncology, and Hematology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea"},{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Bo","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medical Oncology, and Hematology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inkeun","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"},{"name":"Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Jin","family":"Sym","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaekyung","family":"Cheon","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"},{"name":"Department of Hematology and Oncology, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyewon","family":"Ryu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Eul","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Sung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu-pyo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"zoi250966r1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_160831","author":"Bridgewater","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"14","key":"zoi250966r2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"zoi250966r3","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"10391","key":"zoi250966r4","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"zoi250966r5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1200\/JCO.21.00679","article-title":"Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study.","volume":"40","author":"Phelip","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi250966r6","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.4143\/crt.2017.526","article-title":"Multicenter phase II study of oxaliplatin, irinotecan, and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer.","volume":"50","author":"Yoo","year":"2018","journal-title":"Cancer Res Treat"},{"key":"zoi250966r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114196","article-title":"Multicenter phase I\/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer.","volume":"207","author":"Pressiani","year":"2024","journal-title":"Eur J Cancer"},{"issue":"6","key":"zoi250966r8","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial.","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"zoi250966r9","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","article-title":"Hypersensitivity reactions from taxol.","volume":"8","author":"Weiss","year":"1990","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi250966r10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/sj.bjc.6601303","article-title":"Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.","volume":"90","author":"Kloover","year":"2004","journal-title":"Br J Cancer"},{"issue":"1-3","key":"zoi250966r11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0168-3659(01)00275-9","article-title":"In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy.","volume":"72","author":"Kim","year":"2001","journal-title":"J Control Release"},{"issue":"11","key":"zoi250966r12","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1158\/1078-0432.CCR-03-0655","article-title":"Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.","volume":"10","author":"Kim","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"15","key":"zoi250966r13","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1200\/JCO.2003.10.082","article-title":"Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study.","volume":"21","author":"Omura","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi250966r14","first-page":"1038","article-title":"Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.","volume":"8","author":"Ibrahim","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"4","key":"zoi250966r15","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.4143\/crt.2022.1436","article-title":"Safety and tolerability of weekly Genexol-PM, a Cremophor-free polymeric micelle formulation of paclitaxel, with carboplatin in gynecologic cancer: a phase I study.","volume":"55","author":"Nam","year":"2023","journal-title":"Cancer Res Treat"},{"issue":"3","key":"zoi250966r16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.4143\/crt.2016.289","article-title":"An open-label, randomized, parallel, phase III trial evaluating the efficacy and safety of polymeric micelle-formulated paclitaxel compared to conventional Cremophor EL-based paclitaxel for recurrent or metastatic HER2-negative breast cancer.","volume":"49","author":"Park","year":"2017","journal-title":"Cancer Res Treat"},{"issue":"1","key":"zoi250966r17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.annonc.2020.10.479","article-title":"Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial.","volume":"32","author":"Shi","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi250966r18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4143\/crt.2016.376","article-title":"An open-label, randomized, parallel, phase II trial to evaluate the efficacy and safety of a cremophor-free polymeric micelle formulation of paclitaxel as first-line treatment for ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG-3021).","volume":"50","author":"Lee","year":"2018","journal-title":"Cancer Res Treat"},{"issue":"3","key":"zoi250966r19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.21873\/anticanres.11471","article-title":"Multicenter phase II clinical trial of Genexol-PM\u00ae with gemcitabine in advanced biliary tract cancer.","volume":"37","author":"Kim","year":"2017","journal-title":"Anticancer Res"},{"key":"zoi250966r20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01383","article-title":"SWOG S1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers.","author":"Shroff","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi250966r21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000531458","article-title":"Recent advances in systemic therapy for advanced intrahepatic cholangiocarcinoma.","volume":"13","author":"Yoo","year":"2023","journal-title":"Liver Cancer"},{"issue":"1","key":"zoi250966r22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).","volume":"30","author":"Ioka","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"zoi250966r23","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","journal-title":"JAMA"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2839520\/jeong_2025_oi_250966_1761580454.05571.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T15:00:20Z","timestamp":1761836420000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2839520"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.34560","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}